Committee Report Targets FDA, Biogen on Alzheimer's Treatment
A congressional report finds the FDA's approval process for Biogen's Alzheimer's treatment was 'rife with irregularities' that included 'atypical collaboration.' When Biogen's (BII…
A congressional report finds the FDA's approval process for Biogen's Alzheimer's treatment was 'rife with irregularities' that included 'atypical collaboration.' When Biogen's (BII…
